Cao Sean Wuxiong 4

What Happened
Sean Wuxiong Cao, NovaBridge Biosciences' Chief Business Development Officer and a director, disposed of securities on 2026-05-14. The filing reports a sale of ADSs representing approximately 21,399 ordinary shares at $1.99 (price expressed in ADS terms), for a reported total of $42,584. The sale was done solely to satisfy tax withholding obligations arising from a partial vesting of a restricted stock unit (RSU) award.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (period of report 2026-05-14).
• Quantity/price: 9,304 ADSs sold (representing ~21,399 ordinary shares) at $1.99 per ADS; reported proceeds $42,584.
• Transaction codes: S = Sale (disposition); F (tax withholding — sale to cover tax on RSU vesting).
• Reason: Sale executed to satisfy tax withholding for RSU partial vesting on 2026-01-31 (per footnote).
• Holdings after transaction: reported securities are represented by 15,249 ADSs (per filing).
• ADS conversion: 10 ADSs represent 23 ordinary shares (per footnote).

Context
This was a tax-withholding sale tied to RSU vesting, a routine administrative transaction that doesn’t necessarily signal a change in insider sentiment. Retail investors should note the sale’s purpose (tax withholding) and the ADS structure when comparing share counts and dollar amounts.